The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

(2011) M. Dimopoulos et al.   BLOOD

Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney

(2011) C. A. Hutchison et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange

(2011) Brian L. Burnette et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

(2010) Ulrike Klein et al.   ANNALS OF HEMATOLOGY

Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency

(2010) Patrizia Tosi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Immunoglobulin light chains activate nuclear factor- B in renal epithelial cells through a Src-dependent mechanism

(2010) W.-Z. Ying et al.   BLOOD

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

(2010) Meletios Dimopoulos et al.   CANCER

Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients

(2010) Lene Meldgaard Knudsen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Meeting the Unmet Needs in Anticoagulant Therapy

(2010)   EUROPEAN JOURNAL OF HAEMATOLOGY

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study

(2010) Javier De La Rubia et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study

(2009) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells

(2008) R. Sarkozi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

(2008) J F San-Miguel et al.   LEUKEMIA

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

(2008) Maria Roussou et al.   LEUKEMIA & LYMPHOMA